These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 31849454)
1. Molecular Requirements for the Expression of Antiplatelet Effects by Synthetic Structural Optimized Analogues of the Anticancer Drugs Imatinib and Nilotinib. Pantazi D; Ntemou N; Brentas A; Alivertis D; Skobridis K; Tselepis AD Drug Des Devel Ther; 2019; 13():4225-4238. PubMed ID: 31849454 [TBL] [Abstract][Full Text] [Related]
2. Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment. Tullemans BME; Veninga A; Fernandez DI; Aarts MJB; Eble JA; van der Meijden PEJ; Heemskerk JWM; Kuijpers MJE Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681859 [TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials. Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911 [TBL] [Abstract][Full Text] [Related]
6. Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib. Pan X; Dong J; Shao R; Su P; Shi Y; Wang J; He L Bioorg Med Chem Lett; 2015 Oct; 25(19):4164-8. PubMed ID: 26298495 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors. Duveau DY; Hu X; Walsh MJ; Shukla S; Skoumbourdis AP; Boxer MB; Ambudkar SV; Shen M; Thomas CJ Bioorg Med Chem Lett; 2013 Feb; 23(3):682-6. PubMed ID: 23273517 [TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies. El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271 [TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214 [TBL] [Abstract][Full Text] [Related]
10. Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice. Rhee CK; Lee SH; Yoon HK; Kim SC; Lee SY; Kwon SS; Kim YK; Kim KH; Kim TJ; Kim JW Respiration; 2011; 82(3):273-87. PubMed ID: 21659722 [TBL] [Abstract][Full Text] [Related]
11. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Manley PW; Stiefl N; Cowan-Jacob SW; Kaufman S; Mestan J; Wartmann M; Wiesmann M; Woodman R; Gallagher N Bioorg Med Chem; 2010 Oct; 18(19):6977-86. PubMed ID: 20817538 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and anticancer studies of novel aminobenzazolyl pyrimidines as tyrosine kinase inhibitors. Chikhale R; Thorat S; Choudhary RK; Gadewal N; Khedekar P Bioorg Chem; 2018 Apr; 77():84-100. PubMed ID: 29342447 [TBL] [Abstract][Full Text] [Related]
13. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Rix U; Hantschel O; Dürnberger G; Remsing Rix LL; Planyavsky M; Fernbach NV; Kaupe I; Bennett KL; Valent P; Colinge J; Köcher T; Superti-Furga G Blood; 2007 Dec; 110(12):4055-63. PubMed ID: 17720881 [TBL] [Abstract][Full Text] [Related]
14. Direct interaction of the ATP-sensitive K Fröbom R; Berglund E; Aspinwall CA; Lui WO; Nilsson IL; Larsson C; Bränström R Biochem Biophys Res Commun; 2021 Jun; 557():14-19. PubMed ID: 33857840 [TBL] [Abstract][Full Text] [Related]
15. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809 [TBL] [Abstract][Full Text] [Related]
17. Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery. Kim IK; Rhee CK; Yeo CD; Kang HH; Lee DG; Lee SH; Kim JW Crit Care; 2013 Jun; 17(3):R114. PubMed ID: 23787115 [TBL] [Abstract][Full Text] [Related]
18. Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib. Dessilly G; Panin N; Elens L; Haufroid V; Demoulin JB Sci Rep; 2016 Jul; 6():29559. PubMed ID: 27405085 [TBL] [Abstract][Full Text] [Related]
19. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Weisberg E; Wright RD; Jiang J; Ray A; Moreno D; Manley PW; Fabbro D; Hall-Meyers E; Catley L; Podar K; Kung AL; Griffin JD Gastroenterology; 2006 Dec; 131(6):1734-42. PubMed ID: 17087936 [TBL] [Abstract][Full Text] [Related]
20. Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells. Belle L; Bruck F; Foguenne J; Gothot A; Beguin Y; Baron F; Briquet A PLoS One; 2012; 7(12):e52564. PubMed ID: 23285088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]